The immune checkpoint inhibitors available for clinical use primarily target the programmed death 1/program death 1 ligand (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to reprogram the immune system that has been evaded by cancer [16]. This evidence concerns the gene CTLA4 and cancer.